Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. Korro's proprietary and modular platform, OPERA, combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/22 | $116,000,000 | Series B |
Alexandria Venture Investments Atlas Venture Cormorant Asset Management Eventide Asset Management  Fidelity Management & Research Company Invus Monashee Investment Management New Enterprise Associates Point72 Ventures Sixty Degree Capital Surveyor Capital Verition Fund Management | undisclosed |
